跳至主要内容
临床试验/EUCTR2009-011157-41-IT
EUCTR2009-011157-41-IT进行中(未招募)不适用

Efficacy and Safety assessment of T2345 unpreserved eyedrops versus Xalatan in ocular hypertensive or glaucomatous patients. - ND

ABORATORIES THEA0 个研究点目标入组 400 人开始时间: 2009年11月17日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
400

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Patients will be eligible for inclusion if all these criteria are respected: At Selection Visit: - Signed and dated informed consent, - Male or female aged from ≥ 18 to ≤ 90 years old, - Association of the following criteria for the eligible eye(s): - Chronic primary open angle glaucoma or chronic ocular hypertension - Already treated and controlled (since at least one year) by a monotherapy of Xalatan defined by: Stable IOP (≤ 18 mmHg), And Stable visual field defined by two available visual field: the penultimate visual field performed within the last 18 months the last visual field performed within the last 6 months and with an interval of at least 6 months between both visual fields. - Corneal thickness ≥ 510 Mm and ≤ 560 Mm. At Inclusion Visit: - IOP: IOP < 34 mmHg in BOTH eyes And IOP ≥ 22 mmHg in the eligible eye(s).
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Ophthalmic non-inclusion criteria (in either eye) - Any secondary ocular hypertension. - Any severe glaucoma defined by study . - BCVA minor or equal to 1/10. - Aphakia. - Known history of ocular allergy and/or blepharitis and/or uveitis, traumatism, infection, ocular inflammation within the 3 months before the selection Visit, refractive surgery. - Severe dry eye. - Any abnormality preventing accurate assessment. Systemic/non ophthalmic non-inclusion criteria - General history: Non controlled asthma, Any medical or surgical history, disorder or disease and/or any complicating factor or structural abnormality, judged by the investigator to be incompatible with the study. - Known allergic hypersensitivity history to one of the components of the study medications or to test products. Specific non-inclusion criteria for women - Pregnancy, lactation, women without an effective method of contraception or women not hysterectomised, menopaused or surgically sterilized. Non-inclusion criteria related to general conditions - Inability of patient and/or relatives to understand the study procedures and thus inability to give informed consent. - Non compliant patient and/or relatives. - Participation in another clinical study within the last 3 months. - Already included once in this study. - Ward of court. - Patient not covered by the Social Security scheme when existing in the concerned country (NA in Italy).

研究者

发起方
ABORATORIES THEA

相似试验

进行中(未招募)
1 期
Efficacy and Safety assessment of T2345 unpreserved eyedrops versus Xalatan® in ocular hypertensive or glaucomatous patients.Phase III study, multicentre, international, randomised, investigator-masked, 2 parallel groups, versus Reference product, in 400 evaluable patients treated during 3 months.The study population is suffering from glaucoma.MedDRA version: 9.1Level: LLTClassification code 10018304Term: GlaucomaMedDRA version: 9.1Level: PTClassification code 10018304Term: Glaucoma
EUCTR2009-011157-41-FRlaboratoires théa400
进行中(未招募)
1 期
Efficacy and Safety assessment of T2345 unpreserved eyedrops versus Xalatan® in ocular hypertensive or glaucomatous patients.Phase III study, international, multicentre, randomised, investigator-masked, 2 parallel groups, versus reference product, in 360 evaluable patients treated for 3 months.
EUCTR2009-011157-41-ESaboratoires Théa400
进行中(未招募)
不适用
Efficacy and Safety assessment of T2345 unpreserved eyedrops versus Xalatan® in ocular hypertensive or glaucomatous patients.Phase III study, international, multicentre, randomised, investigator-masked, 2 parallel groups, versus reference product, in 360 evaluable patients treated for 3 months.The study population will be suffering from open angle glaucoma or hypertension.MedDRA version: 12.0Level: LLTClassification code 10030348Term: Open angle glaucomaMedDRA version: 12.0Level: LLTClassification code 10030043Term: Ocular hypertension
EUCTR2009-011157-41-BEaboratoires Théa400
进行中(未招募)
不适用
Efficacy and Safety assessment of LT2345 unpreserved eye drops versus Xalatan in ocular hypertensive ou glaucomatous patients.PHase III study, international, multicentre, randomised, investigator masked, 2 parallel groups, versus reference product in 360 evaluable patents treated for 3 months.The study population is suffering from glaucoma.
EUCTR2009-011157-41-PTaboratoires Thea400
已完成
2 期
Pharmacokinetics, Efficacy and Safety Assessment of T2345 Compared With Active Comparator in Newly Diagnosed Patients With Open-angle Glaucoma or Ocular HypertensionPrimary Open Angle Glaucoma
NCT01494753Laboratoires Thea30